Conflicting results of in-situ ICP changes probably arise from i) the heterogeneity of BC in terms of molecular profiles and oncogenic mechanisms among different types or subtypes of breast cancer [28], ii) cut-off points to establish positivity for certain markers, iii) the use of different anti PD-L1 antibodies [71], and iv) differences in the activation status of T cells and their cytokine production in response to NAC [23]. This evidence concerns the gene CD274 and breast carcinoma.